miRNA expression in COVID-19.
Gene Rep
; 28: 101641, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-1936453
ABSTRACT
Coronavirus disease 2019 (COVID-19) is regarded as a challenge in health system. Several studies have assessed the immune-related aspect of this disorder to identify the host-related factors that affect the course of COVID-19. microRNAs (miRNAs) as potent regulators of immune responses have gained much attention in this regard. Recent studies have shown aberrant expression of miRNAs in COVID-19 in association with disease course. Differentially expressed miRNAs have been enriched in pathways related with inflammation and antiviral immune response. miRNAs have also been regarded as potential therapeutic targets in COVID-19, particularly for management of pathological consequences of COVID-19. In the current review, we summarize the data about dysregulation of miRNAs in COVID-19.
ACE2, Angiotensin-converting enzyme 2; ARDS, Acute respiratory distress syndrome; COVID-19; COVID-19, Coronavirus disease 2019; HDAC, Histone deacetylate; HMVEC, Human Lung Microvascular Endothelial Cells; ORF, Open reading frame; ROC, Receiver operating characteristic; SARS-CoV-2; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; TLR, Toll-like receptor; TMPRSS2, Transmembrane protease serine 2; UTR, Untranslated region; hBMEC, Human brain microvascular endothelial cells; miRNA; miRNAs, microRNAs
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
Gene Rep
Year:
2022
Document Type:
Article
Affiliation country:
J.genrep.2022.101641
Similar
MEDLINE
...
LILACS
LIS